Clinical trial NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Humanized Monoclonal Antibody Specific to B- and T- Lymphocyte Attenuator, BTLA (JS004) Injection in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Melanoma
Renal Carcinoma
Urothelial Carcinoma
Lead sponsor: Shanghai Junshi Bioscience Co., Ltd.
Sponsor class: OTHER
First posted: 2021-02-26
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An open-label, dose-escalation, phase I clinical study to evaluate the safety and tolerability of JS004 injection in the patients with advanced solid tumors who have failure in standard of care and are unable to tolerate standard of care and/or have no available standard of care. The study is divided into screening period, treatment period, and follow-up period.

1. Screening period: Subjects will be included in the screening period after signing the informed consent form (ICF). The screening period is up to 28 days, subjects will enter the study treatment period if they meet all the inclusion criteria and none of exclusion criterion.
2. Treatment period: Subjects will be allocated to the designated dose group to receive corresponding treatment in accordance with the progress of study. Subjects in dose escalation phase will receive DLT observation at first, and upon completion of DLT observation, the subjects will continue their administration at the original dose if they are tolerated as judged by investigator, until progression of disease, intolerable toxicity or other reasons specified in the protocol. Subjects in the dose extension phase receive appropriate study treatment until disease progression, intolerance of toxicity, or other causes specified in the protocol occur. Response evaluation criteria in solid tumors (RECIST v1.1) will be used for efficacy evaluation every 9 weeks (±7 days) in the first year and every 12 weeks (±7 days) in the 2nd year and thereafter.
3. Follow-up period: A safety follow-up visit is required 30 days (±7 days) after the last dose of study drug or before the initiation of new antitumor therapy. If the new antitumor therapy has not been initiated, additional safety follow-up should be completed 90 days (±7 days) after the last dose as far as possible.


Eligibility criteria: Inclusion Criteria:

Only the patients meeting the following criteria are eligible to participate in the study:

1. Voluntarily signed written informed consent form;
2. Age ≥18 and ≤70 years at the time of signing informed consent form, male or female;
3. Life expectancy ≥ 3 months;
4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;
5. Patients with histologically or cytologically confirmed advanced solid tumors: patients with advanced solid tumors who have failure in standard of care, cannot tolerate standard of care, refuse and/or have no standard of care (melanoma, renal carcinoma and urothelial carcinoma);
6. At least one measurable lesion as target lesion (RECIST v1.1);
7. Agree to provide tumor tissue specimen ( fresh biopsied sample before treatment should be provided as far as possible, the archived sample within two years is acceptable for the patients who cannot provide fresh biopsied sample before treatment);
8. Adequate organ function as indicated by the laboratory results during the screening period;
9. Use of effective contraceptive methods during the study for male subjects of reproduction ability or female subjects of childbearing potential, and continuation of contraception for 6 months after the end of treatment;
10. Good compliance, cooperation with follow-up.

Exclusion Criteria

Patients will be excluded from the study when they have any of the following conditions:

1. History of malignant tumors other than the disease investigated in the past 5 years, however, except for the malignant tumors that can be expected to be cured after treatment;
2. Having received systematic antitumor therapy, or local antitumor therapy, or treatment with clinically investigational medication or device within 4 weeks prior to the first dose of study drug;
3. Having received immunotherapy within 4 weeks prior to first dose of study drug;
4. Previously treated with anti-BTLA or anti-HVEM antibody;
5. Adverse reaction induced by previous therapy having not recovered to CTCAE (version 5.0) grade 1 or better;
6. Having previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
7. Having central nervous system metastases and/or cancerous meningitis;
8. Having or suspected to have active autoimmune disease;
9. Having hepatitis and liver cirrhosis;
10. Massive hydrothorax or ascites with clinical symptoms or requiring symptomatic treatment;
11. Having severe cerebro- and cardiovascular diseases;
12. Having pulmonary disease;
13. Having active infection requiring systemic treatment;
14. Positive result for human immunodeficiency virus (HIV) antibody;
15. Active hepatitis B or C;
16. Known active tuberculosis (TB);
17. Use of systemic corticosteroids 14 days prior to the first dose of study drug;
18. Use of broad-spectrum antibiotics that may affect the change of intestinal flora within 14 days prior to the first dose of study drug;
19. Vaccination of live vaccine within 4 weeks prior to the first dose of study drug;
20. Having received major surgery within 4 weeks prior to the first dose of study drug;
21. History of anti-psychotics abuse and unable to abstain, or with a history of mental disorder;
22. Pregnant or breast-feeding women;
23. Known allergy to JS004 and its components;
24. Other severe, acute or chronic medical conditions or mental diseases or laboratory abnormalities possibly increasing relevant risks in participation in the study or possibly interfering with the interpretation of study results as judged by investigators.

Primary outcomes:
measure: To evaluate the safety and tolerability of JS004 injection alone and in combination with Toripalimab in patients with advanced solid tumors.
timeFrame: 2 years
measure: Determine the maximum tolerated dose (MTD)/recommended extended dose (RDE) of JS004 injection monotherapy and combination with Toripalimab in patients with advanced solid tumors.
timeFrame: 2 years
Secondary outcomes:
measure: To preliminarily evaluate the efficacy of JS004 injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
measure: To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.
timeFrame: 2 years
Other outcomes:
measure: To exploratively evaluate the antitumor activity of JS004 injection as a single drug and combined with Toripalimab using iRECIST (2017).
timeFrame: 2 years
measure: To explore the pharmacodynamic profile of JS004 injection.
timeFrame: 2 years
measure: To explore the correlation of relevant biomarkers with clinical efficacy.
timeFrame: 2 years
Locations:
city: Fuzhou
country: China
facility: Fujian Provincial Cancer Hospital
state: Fujian
city: Harbin
country: China
facility: Tumor Hospital affiliated to Harbin Medical University
state: Heilongjiang
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital
state: Jiangsu
city: Changchun
country: China
facility: First Hospital of Jilin University
state: Jilin
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
state: Sichuan
city: Hangzhou
country: China
facility: Run Run Shaw Hospital affiliated to Zhejiang University Medical College
state: Zhejiang
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Wuhan
country: China
facility: Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Jun Guo
role: PRINCIPAL_INVESTIGATOR
References: